Home > News > Headline News > Archive

Click on title to read the full article.

Are Metastatic Breast Cancer Patients Getting the Right Treatment?

October 27, 2010

By Melissa Weber, CureToday.com

As many as one in seven women with metastatic breast cancer could be receiving the wrong treatment because of a change in the cancer’s biology when it metastasizes, according to new research.

Insurers Test New Cancer Pay Systems

October 20, 2010

Several large health insurers, including UnitedHealthcare and Aetna, are focusing on one of the country's most costly diseases: cancer

Cancer Screening Continues Even after Patients Are Diagnosed with Terminal Cancer

October 20, 2010

By National Cancer Institute

A number of patients with advanced, incurable cancer continue to undergo routine cancer screening tests that are unlikely to provide any medical benefit, reported researchers led by Dr. Camelia Sima from Memorial Sloan-Kettering Cancer Center in the October 13 issue of the Journal of the American Medical Association (JAMA).

Partners in Crime: Using Synthetic Lethality to Identify New Cancer Targets

October 19, 2010

By National Cancer Institute NCI

One of the big stories of the past year in cancer research has been the emergence of several agents that target an enzyme known as PARP1. Early-stage clinical trials involving women who have particularly difficult-to-treat types of breast cancer, including tumors with a mutated form of either the BRCA1 or BRCA2 gene, have shown that treatment with drugs that block PARP1 produced promising results.

New Oncologist Survey Reveals Gaps in Care for Canadians Living with Metastatic Cancer

October 13, 2010

By Canadian Breast Cancer Network

OTTAWA, Oct. 13 /CNW/ - To mark Metastatic Breast Cancer Awareness Day, the Canadian Breast Cancer Network (CBCN) has unveiled new insights into the challenges facing Canadians living with advanced, or metastatic, cancer.

Recognizing a Day of National Metastatic Breast Cancer Awareness

October 13, 2010

By Dr. Elaine Schattner, Huffington Post

Tired of seeing pink? You’re not alone, says Dr. Barron Lerner in a piece on Pink Ribbon Fatigue in the New York Times. While cancer awareness campaigns have heightened awareness about this condition, lessened women’s fear of the disease and helped raise needed funds for research and care, some are finding the whole pink thing a bit too much.

But for more than 160,000 women living in the U.S. with advanced, stage IV breast cancer, the situation is not one they can turn off on their TV sets, or avoid by skipping out from pink-decorated malls: they’re living and coping with the metastatic form of the disease, active treatments, side effects and, still, no known cure. Their outlook is tempered, maybe best portrayed in a spectrum of gray.

Triple-Negative Breast Cancer Responds Well To Cetuximab Addition To Chemotherapy

October 13, 2010

By Medical News Today

Women with metastatic triple-negative breast cancer respond twice as well to chemotherapy if Cetuximab is added, researchers revealed at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

Identifying subsets of patients who will respond to subsequent lines of chemotherapy

October 11, 2010

By Genetic Engineering & Biotechnology News

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy

Chemotherapy Beyond the Third Line May Benefit Subset of Patients With Metastatic Breast Cancer

October 10, 2010

By Roxanne Nelson, Medscape Medical News

October 10, 2010 (Milan, Italy) — In metastatic breast cancer, going beyond third-line chemotherapy can be successful in some patients, but identifying which subsets of patients have the best chance of benefit remains unclear

Iniparib Improves Survival in Metastatic Triple-Negative Breast Cancer

October 10, 2010

By Roxanne Nelson, Medscape Medical News

October 10, 2010 (Milan, Italy) — An investigational agent appears to extend survival in women with metastatic triple-negative breast cancer, according to new data.

 1 2 >